David Becker, MD, FACC, Director of the Preventive and Integrative Heart Health Program at the Temple Heart and Vascular Institute, wrote a blog post for the Philadelphia Inquirer about high blood pressure, or hypertension.
David Becker, MD, FACC, Director of the Preventive and Integrative Heart Health Program at the Temple Heart and Vascular Institute, wrote a blog post for the Philadelphia Inquirer about high blood pressure, or hypertension.
Patients who received tezepelumab vs. placebo had less healthcare resource utilization; and fewer patients on tezepelumab vs. placebo received systemic corticosteroids for COPD exacerbations.
Read MoreThe analysis looked at sotatercept use in patients with pulmonary arterial hypertension and the safety and utilization across phenotype groups.
Read More